Navigation Links
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Date:1/5/2009

    Singapore investigators to coordinate 700 patient trial of EGFR targeting
    antibody for treatment of head and neck cancer

MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, YM's EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs. The trial is sponsored by the NCCS in collaboration with Innogene Kalbiotech Pte. Ltd, ("IGK") YM's licensee for nimotuzumab for the region.

"The efficacy of nimotuzumab as an epidermal growth factor receptor targeted therapy is likely to be comparable to drugs of the same class. However, what is likely to set nimotuzumab apart is its low toxicity and favourable safety profile," said Dr. Rikrik Ilyas, Director of IGK. "Patients are spared the discomfort of severe skin rashes and may benefit from an enhanced quality of life. Both patients and physicians may also benefit from lack of hypomagnesemia often related to treatment with other anti-EGFR targeted drugs. IGK is pleased to support the NCCS in this investigator-initiated trial of nimotuzumab."

The NCCS is the lead cancer centre coordinating this clinical trial, which will involve approximately 22 institutions from 12 countries worldwide. The trial will treat patients with locally advanced squamous cell cancers of the head and neck immediately following surgery - the "adjuvant setting". Along with standard chemotherapy and radiotherapy, half of the patients will be administered nimotuzumab weekly for an eight week period. The primary endpoint for th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
(Date:3/26/2015)... NJ (PRWEB) March 26, 2015 WriteResult, ... partnered with researchers from Yale University’s School of Public ... by study participants during a 4 month-long project. The ... of providing low income families with free access to ... habits and diet-related health concerns like high blood pressure, ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... Jan. 18, 2011 Ingenuity® Systems, a leading ... and Erasmus Medical Center, jointly announced a scientific ...   As part of the collaboration, ... to derive the most impactful biological insights from ...
... SEATTLE, Jan. 14, 2011 Dendreon Corporation (Nasdaq: ... public offering of $540 million aggregate principal amount of ... "Notes") in an offering registered under the Securities Act ... upsized from its previously announced $500 million offering.  The ...
... Registration is now open for StemCONN 2011. ... discoveries in stem cell research, will take place Tuesday, ... (scientific session) and the UConn Health Center (commercial session ... website at http://stemconn.org/ . StemCONN 2011 ...
Cached Biology Technology:Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research 2Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 2Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 3Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 4
(Date:3/10/2015)... 10, 2015 Transforming How We ... "Personalized Medicine in Human Space Flight" by ... Goodwin , Ph.D. was recently featured by Springer Science ... years. Specifically, "Personalized Medicine in Human Space ... published in 2013 and 2014 from Springer in the ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... This release is available in French . ... Farmers around the world rely, at least in part on phosphorus-based ... overuse of phosphorus can lead to freshwater pollution and the development ... algae in lakes and the growth of coastal ,dead zones,. ...
... In the search for life on Mars or any planet, ... oxygen to consider. Using Earth,s biogeochemical cycles as a reference ... important for supporting life. As explored in studies published in ... Environment, the most basic elements work together to support an ...
... National Institute of Standards and Technology (NIST) will no ... of the mercury thermometer calibration program marks the end ... service since the doors opened in 1901. The closing ... in collaboration with the U.S. Environmental Protection Agency (EPA) ...
Cached Biology News:Helping feed the world without polluting its waters 2Earth's life support systems discussed in an open-access special issue 2End of an era: NIST to cease calibrating mercury thermometers 2
TP-1 (NDOG1)...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... KLH-conjugated, synthetic peptide corresponding to ... mouse p19ARF. The epitope ... 62-75. Clone 5-C3-1. Quality ... immunoblot. Stability ...
Biology Products: